1. Patient-Derived Orthotopic Xenografts and Cell Lines from Pediatric High-Grade Glioma Recapitulate the Heterogeneity of Histopathology, Molecular Signatures, and Drug Response
- Author
-
Chen He, Brian Gudenas, James Dalton, Jason Chiang, Zoran Rankovic, Chang-Hyuk Kwon, Nathaniel R. Twarog, Wenwei Lin, Amar Gajjar, Michelle Monje, Ke Xu, Lawryn H. Kasper, Laura D. Hover, Brent A. Orr, Taosheng Chen, Burgess B. Freeman, Gang Wu, Kimberly S Mercer, Santhosh A. Upadhyaya, Paul Klimo, Yingzhe Wang, Giles W. Robinson, William Caufield, Paige S. Dunphy, Martine F. Roussel, Suzanne J. Baker, Ibrahim Qaddoumi, Cynthia Wetmore, Xiaoyu Li, Jinghui Zhang, Anang A. Shelat, Duane G. Currier, Barbara Jonchere, Christopher L. Tinkle, Paul A. Northcott, Alberto Broniscer, Frederick A. Boop, Junyuan Zhang, and Xiaoyan Zhu
- Subjects
Pathogenesis ,In vivo ,Glioma ,DNA methylation ,Cancer research ,medicine ,Context (language use) ,Biology ,Signal transduction ,medicine.disease ,PI3K/AKT/mTOR pathway ,In vitro - Abstract
Pediatric high-grade glioma (pHGG) is a major contributor to cancer-related death in children.In vitroandin vivodisease models reflecting the intimate connection between developmental context and pathogenesis of pHGG are essential to advance understanding and identify therapeutic vulnerabilities. We established 21 patient-derived pHGG orthotopic xenograft (PDOX) models and eight matched cell lines from diverse groups of pHGG. These models recapitulated histopathology, DNA methylation signatures, mutations and gene expression patterns of the patient tumors from which they were derived, and included rare subgroups not well-represented by existing models. We deployed 16 new and existing cell lines for high-throughput screening (HTS).In vitroHTS results predicted variablein vivoresponse to inhibitors of PI3K/mTOR and MEK signaling pathways. These unique new models and an online interactive data portal to enable exploration of associated detailed molecular characterization and HTS chemical sensitivity data provide a rich resource for pediatric brain tumor research.
- Published
- 2020
- Full Text
- View/download PDF